Literature DB >> 26945549

Bruton's Tyrosine Kinase Deficiency Inhibits Autoimmune Arthritis in Mice but Fails to Block Immune Complex-Mediated Inflammatory Arthritis.

Lindsay E Nyhoff1, Bridgette L Barron1, Elizabeth M Johnson1, Rachel H Bonami1, Damian Maseda1, Benjamin A Fensterheim1, Wei Han1, Timothy S Blackwell1, Leslie J Crofford1, Peggy L Kendall1.   

Abstract

OBJECTIVE: Bruton's tyrosine kinase (BTK) is a B cell signaling protein that also contributes to innate immunity. BTK inhibitors prevent autoimmune arthritis but have off-target effects, and the mechanisms of protection remain unknown. We undertook these studies using genetic deletion to investigate the role of BTK in adaptive and innate immune responses that drive inflammatory arthritis.
METHODS: BTK-deficient K/BxN mice were generated to study the role of BTK in a spontaneous model that requires both adaptive and innate immunity. The K/BxN serum-transfer model was used to bypass the adaptive system and elucidate the role of BTK in innate immune contributions to arthritis.
RESULTS: BTK deficiency conferred disease protection to K/BxN mice, confirming outcomes of BTK inhibitors. B lymphocytes were profoundly reduced, more than in other models of BTK deficiency. Subset analysis revealed loss of B cells at all developmental stages. Germinal center B cells were also decreased, with downstream effects on numbers of follicular helper T cells and greatly reduced autoantibodies. In contrast, total IgG was only mildly decreased. Strikingly, and in contrast to small molecule inhibitors, BTK deficiency had no effect in the serum-transfer model of arthritis.
CONCLUSION: BTK contributes to autoimmune arthritis primarily through its role in B cell signaling and not through innate immune components.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26945549      PMCID: PMC5668904          DOI: 10.1002/art.39657

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  54 in total

Review 1.  B cell antigen receptor signaling 101.

Authors:  Joseph M Dal Porto; Stephen B Gauld; Kevin T Merrell; David Mills; Aimee E Pugh-Bernard; John Cambier
Journal:  Mol Immunol       Date:  2004-07       Impact factor: 4.407

2.  Structural evaluation of BTK and PKCδ mediated phosphorylation of MAL at positions Tyr86 and Tyr106.

Authors:  Rehan Zafar Paracha; Amjad Ali; Jamil Ahmad; Riaz Hussain; Umar Niazi; Syed Aun Muhammad
Journal:  Comput Biol Chem       Date:  2014-04-20       Impact factor: 2.877

3.  Tracking the response of Xid B cells in vivo: TI-2 antigen induces migration and proliferation but Btk is essential for terminal differentiation.

Authors:  C G Vinuesa; Y Sunners; J Pongracz; J Ball; K M Toellner; D Taylor; I C MacLennan; M C Cook
Journal:  Eur J Immunol       Date:  2001-05       Impact factor: 5.532

4.  Molecular imaging of folate receptor β-positive macrophages during acute lung inflammation.

Authors:  Wei Han; Rinat Zaynagetdinov; Fiona E Yull; Vasiliy V Polosukhin; Linda A Gleaves; Harikrishna Tanjore; Lisa R Young; Todd E Peterson; H Charles Manning; Lawrence S Prince; Timothy S Blackwell
Journal:  Am J Respir Cell Mol Biol       Date:  2015-07       Impact factor: 6.914

5.  RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.

Authors:  Daigen Xu; Yong Kim; Jennifer Postelnek; Minh Diem Vu; Dong-Qing Hu; Cheng Liao; Mike Bradshaw; Jonathan Hsu; Jun Zhang; Achal Pashine; Dinesh Srinivasan; John Woods; Anita Levin; Alison O'Mahony; Timothy D Owens; Yan Lou; Ronald J Hill; Satwant Narula; Julie DeMartino; Jay S Fine
Journal:  J Pharmacol Exp Ther       Date:  2012-01-06       Impact factor: 4.030

6.  Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia.

Authors:  Katja Fiedler; Anca Sindrilaru; Grzegorz Terszowski; Enikö Kokai; Thorsten B Feyerabend; Lars Bullinger; Hans-Reimer Rodewald; Cornelia Brunner
Journal:  Blood       Date:  2010-11-09       Impact factor: 22.113

Review 7.  Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis.

Authors:  Katrina E Donahue; Gerald Gartlehner; Daniel E Jonas; Linda J Lux; Patricia Thieda; Beth L Jonas; Richard A Hansen; Laura C Morgan; Kathleen N Lohr
Journal:  Ann Intern Med       Date:  2007-11-19       Impact factor: 25.391

8.  The cellular source and target of IL-21 in K/BxN autoimmune arthritis.

Authors:  Katharine E Block; Haochu Huang
Journal:  J Immunol       Date:  2013-08-19       Impact factor: 5.422

9.  Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.

Authors:  Andrew L Rankin; Nilufer Seth; Sean Keegan; Tatyana Andreyeva; Tim A Cook; Jason Edmonds; Nagappan Mathialagan; Micah J Benson; Jameel Syed; Yutian Zhan; Stephen E Benoit; Joy S Miyashiro; Nancy Wood; Shashi Mohan; Elena Peeva; Shashi K Ramaiah; Dean Messing; Bruce L Homer; Kyri Dunussi-Joannopoulos; Cheryl L Nickerson-Nutter; Mark E Schnute; John Douhan
Journal:  J Immunol       Date:  2013-09-25       Impact factor: 5.422

10.  Independent and opposing roles for Btk and lyn in B and myeloid signaling pathways.

Authors:  A B Satterthwaite; C A Lowell; W N Khan; P Sideras; F W Alt; O N Witte
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307

View more
  11 in total

1.  Reply.

Authors:  Lindsay E Nyhoff; Leslie J Crofford; Peggy L Kendall
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

Review 2.  The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.

Authors:  Leslie J Crofford; Lindsay E Nyhoff; Jonathan H Sheehan; Peggy L Kendall
Journal:  Expert Rev Clin Immunol       Date:  2016-03-04       Impact factor: 4.473

Review 3.  Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies.

Authors:  Jolan E Walter; Jocelyn R Farmer; Zsofia Foldvari; Troy R Torgerson; Megan A Cooper
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Nov - Dec

4.  New Perspectives in Rheumatology: May You Live in Interesting Times: Challenges and Opportunities in Lupus Research.

Authors:  Iñaki Sanz
Journal:  Arthritis Rheumatol       Date:  2017-06-16       Impact factor: 10.995

5.  Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.

Authors:  Philipp Haselmayer; Montserrat Camps; Lesley Liu-Bujalski; Ngan Nguyen; Federica Morandi; Jared Head; Alison O'Mahony; Simone C Zimmerli; Lisa Bruns; Andrew T Bender; Patricia Schroeder; Roland Grenningloh
Journal:  J Immunol       Date:  2019-04-15       Impact factor: 5.422

Review 6.  Autoimmunity in Primary Immunodeficiencies (PID).

Authors:  Grace T Padron; Vivian P Hernandez-Trujillo
Journal:  Clin Rev Allergy Immunol       Date:  2022-06-01       Impact factor: 8.667

Review 7.  Bruton's Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus.

Authors:  Anne B Satterthwaite
Journal:  Front Immunol       Date:  2018-01-22       Impact factor: 7.561

Review 8.  Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.

Authors:  Garth E Ringheim; Matthew Wampole; Kinsi Oberoi
Journal:  Front Immunol       Date:  2021-11-03       Impact factor: 7.561

9.  T-B Lymphocyte Interactions Promote Type 1 Diabetes Independently of SLAM-Associated Protein.

Authors:  Rachel H Bonami; Lindsay E Nyhoff; Dudley H McNitt; Chrys Hulbert; Jamie L Felton; Peggy L Kendall; James W Thomas
Journal:  J Immunol       Date:  2020-11-16       Impact factor: 5.422

Review 10.  Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies.

Authors:  Stefan F H Neys; Rudi W Hendriks; Odilia B J Corneth
Journal:  Front Cell Dev Biol       Date:  2021-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.